INT2464

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 1979
Last Reported 2010
Negated 3
Speculated 0
Reported most in Abstract
Documents 21
Total Number 21
Disease Relevance 13.76
Pain Relevance 2.78

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (AMY2A) small molecule metabolic process (AMY2A) hydrolase activity, acting on glycosyl bonds (AMY2A)
extracellular region (AMY2A) carbohydrate metabolic process (AMY2A)
Anatomy Link Frequency
acinar cells 2
shields 2
pancreas 1
brain 1
epithelial cells 1
AMY2A (Homo sapiens)
Pain Link Frequency Relevance Heat
Cholecystokinin 11 99.98 Very High Very High Very High
Pain 8 97.64 Very High Very High Very High
headache 9 96.96 Very High Very High Very High
fibrosis 1 96.92 Very High Very High Very High
Thalamus 4 96.64 Very High Very High Very High
agonist 18 91.52 High High
antagonist 6 90.24 High High
Paracetamol 6 87.72 High High
abdominal pain 4 85.84 High High
Codeine 11 84.32 Quite High
Disease Link Frequency Relevance Heat
Cancer 90 99.76 Very High Very High Very High
Hyperamylasemia 8 99.52 Very High Very High Very High
Adenocarcinoma 137 98.64 Very High Very High Very High
Cirrhosis 54 97.92 Very High Very High Very High
Myalgia 9 97.80 Very High Very High Very High
Pain 8 97.64 Very High Very High Very High
Fatigue 9 97.32 Very High Very High Very High
Chronic Hepatitis 54 97.12 Very High Very High Very High
Headache 9 96.96 Very High Very High Very High
Fibrosis 7 96.92 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Results of tPA-Ag and PAI-Ag are expressed in ng/ml.
Gene_expression (expressed) of PAI
1) Confidence 0.75 Published 2002 Journal BMC Cardiovasc Disord Section Body Doc Link PMC115848 Disease Relevance 0.05 Pain Relevance 0.04
Three adenocarcinomas that clustered away from the majority of adenocarcinomas (shcx173, shcx172b, and shcx150) were distinguished by significant expression of genes encoding digestive enzymes, such as pancreatic amylase (AMY2A) and elastase (ELA3A), suggesting the presence of normal acinar cells in addition to the neoplastic component.
Gene_expression (expression) of AMY2A in acinar cells associated with adenocarcinoma
2) Confidence 0.75 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1824711 Disease Relevance 1.48 Pain Relevance 0
The simultaneous analysis and computer modeling of competition and saturation experiments performed in the same subjects indicated that a high proportion of alpha-2A adrenoceptors exist in the RH conformation (70-80%).
Gene_expression (proportion) of alpha-2A
3) Confidence 0.67 Published 1994 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7912275 Disease Relevance 0.16 Pain Relevance 0.41
Genes encoding digestive enzymes produced by acinar cells such as amylase (AMY2A), elastase (ELA3A, ELA3B), carboxypeptidase A (CPA2), pancreatic lipase (PNLIP), and trypsin (PRSS2) were enriched in this cluster (Figures 1, “Acinar” cluster).
Gene_expression (produced) of AMY2A in acinar cells
4) Confidence 0.65 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1824711 Disease Relevance 1.08 Pain Relevance 0.06
Studies of PAI-deficient or overexpressing mice indicate that PAI-1 regulates the amount of collagen deposition in the lung [27].
Gene_expression (overexpressing) of PAI in lung
5) Confidence 0.58 Published 2002 Journal Genome Biol Section Body Doc Link PMC115222 Disease Relevance 0.76 Pain Relevance 0.21
The markedly raised levels of serum-alpha-amylase (mean of 21 700 U/l immediately before the procedure) fell tonormal values within 48 hours (400--3000 U/l).
Gene_expression (levels) of serum-alpha-amylase
6) Confidence 0.49 Published 1980 Journal Dtsch. Med. Wochenschr. Section Abstract Doc Link 7351193 Disease Relevance 0.80 Pain Relevance 0.18
The tumor cells were negative for C-erbB2, MUC1, trypsin, pancreatic amylase and pancreatic lipase.
Neg (negative) Gene_expression (negative) of pancreatic amylase associated with cancer
7) Confidence 0.27 Published 2009 Journal Pathol. Int. Section Abstract Doc Link 19121093 Disease Relevance 1.02 Pain Relevance 0.06
The 168 pmol kg-1 h-1 dose of CCK produced maximal pancreatic amylase output.
Gene_expression (produced) of pancreatic amylase associated with cholecystokinin
8) Confidence 0.08 Published 1979 Journal Gastroenterology Section Abstract Doc Link 447032 Disease Relevance 0.21 Pain Relevance 0.44
For instance, PGE1 stimulated the production and secretion of alpha-amylase from minces of porcine pancreas in vitro [14], and enzyme output in dogs in vivo [15].
Gene_expression (production) of alpha-amylase in pancreas
9) Confidence 0.06 Published 2004 Journal BMC Womens Health Section Body Doc Link PMC406515 Disease Relevance 0.56 Pain Relevance 0.53
The alpha-2A and alpha-2C subtypes are widely distributed in the brain, including the PFC, the alpha-2B receptor is most concentrated in the thalamus.
Gene_expression (distributed) of alpha-2A in brain associated with thalamus
10) Confidence 0.04 Published 2008 Journal Behav Brain Funct Section Body Doc Link PMC2289834 Disease Relevance 0.16 Pain Relevance 0.31
Peginterferon-alpha-2a (40KD) produced histological responses in patients (with or without cirrhosis) with or without a sustained virological response.
Gene_expression (produced) of Peginterferon-alpha-2a associated with cirrhosis
11) Confidence 0.04 Published 2002 Journal BioDrugs Section Abstract Doc Link 12102649 Disease Relevance 0.84 Pain Relevance 0.06
Peginterferon-alpha-2a (40 kD) produced better results than interferon-alpha-2a alone or interferon-alpha-2b plus oral ribavirin on various measures of quality of life in patients with chronic hepatitis C.
Gene_expression (produced) of Peginterferon-alpha-2a associated with chronic hepatitis
12) Confidence 0.04 Published 2001 Journal Drugs Section Abstract Doc Link 11772139 Disease Relevance 0.84 Pain Relevance 0.07
Peginterferon-alpha-2a (40KD) produced better results than interferon-alpha-2a alone or interferon-alpha-2b plus oral ribavirin on various measures of quality of life in patients with chronic hepatitis C.
Gene_expression (produced) of Peginterferon-alpha-2a associated with chronic hepatitis
13) Confidence 0.04 Published 2002 Journal BioDrugs Section Abstract Doc Link 12102649 Disease Relevance 0.84 Pain Relevance 0.07
Peginterferon-alpha-2a (40KD) is produced by the covalent attachment of recombinant interferon-alpha-2a to a branched mobile 40KD polyethylene glycol moiety, which shields the interferon-alpha-2a molecule from enzymatic degradation, reduces systemic clearance and enables once-weekly administration.
Gene_expression (produced) of Peginterferon-alpha-2a in shields
14) Confidence 0.04 Published 2002 Journal BioDrugs Section Abstract Doc Link 12102649 Disease Relevance 0.20 Pain Relevance 0
Peginterferon-alpha-2a (40 kD) is produced by the covalent attachment of recombinant interferon-alpha-2a to a branched mobile 40 kD polyethylene glycol moiety, which shields the interferon-alpha-2a molecule from enzymatic degradation, reduces systemic clearance and enables once-weekly administration.
Gene_expression (produced) of Peginterferon-alpha-2a in shields
15) Confidence 0.04 Published 2001 Journal Drugs Section Abstract Doc Link 11772139 Disease Relevance 0.20 Pain Relevance 0
In conclusion, peginterferon-alpha-2a (40KD) administered once weekly produces significantly higher sustained responses, without compromising tolerability, than interferon-alpha-2a administered thrice weekly in noncirrhotic or cirrhotic patients with chronic hepatitis C, including those infected with HCV genotype 1 - a group in whom interferon-alpha treatment has usually been unsuccessful.
Neg (without) Gene_expression (produces) of peginterferon-alpha-2a associated with chronic hepatitis, cirrhosis and hepatitis c virus infection
16) Confidence 0.03 Published 2002 Journal BioDrugs Section Abstract Doc Link 12102649 Disease Relevance 1.18 Pain Relevance 0.10
Peginterferon-alpha-2a (40 kD) was significantly more effective than interferon-alpha-2a in interferon-alpha therapy-naive adults with chronic hepatitis C in three nonblind, randomised, multicentre trials.
Gene_expression (effective) of Peginterferon-alpha-2a associated with chronic hepatitis
17) Confidence 0.03 Published 2001 Journal Drugs Section Abstract Doc Link 11772139 Disease Relevance 0.25 Pain Relevance 0
CONCLUSION: Peginterferon-alpha-2a (40 kD) administered once weekly produces significantly higher sustained responses, without compromising tolerability, than interferon-alpha-2a administered thrice weekly in noncirrhotic or cirrhotic patients with chronic hepatitis C, including those infected with HCV genotype 1 - a group in whom interferon-alpha treatment has usually been unsuccessful.
Neg (without) Gene_expression (produces) of Peginterferon-alpha-2a associated with chronic hepatitis, cirrhosis and hepatitis c virus infection
18) Confidence 0.03 Published 2001 Journal Drugs Section Abstract Doc Link 11772139 Disease Relevance 1.18 Pain Relevance 0.10
Peginterferon-alpha-2a (40 kD) produced histological responses in patients (with or without cirrhosis) with or without a sustained virological response.
Gene_expression (produced) of Peginterferon-alpha-2a associated with cirrhosis
19) Confidence 0.03 Published 2001 Journal Drugs Section Abstract Doc Link 11772139 Disease Relevance 0.83 Pain Relevance 0.06
Thirty-nine of 57 patients (68%) had pancreatic hyperamylasemia as expected, but 18 of 57 patients (32%) had normal levels of pancreatic amylase.
Gene_expression (levels) of pancreatic amylase associated with hyperamylasemia
20) Confidence 0.02 Published 1982 Journal Surgery Section Abstract Doc Link 6181574 Disease Relevance 1.13 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox